{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:16:35Z","timestamp":1792757795546,"version":"4.5.0"},"reference-count":232,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>The most prevalent cause of dementia is Alzheimer\u2019s disease. Cognitive decline and accelerating memory loss characterize it. Alzheimer\u2019s disease advances sequentially, starting with preclinical stages, followed by mild cognitive and\/or behavioral impairment, and ultimately leading to Alzheimer\u2019s disease dementia. In recent years, healthcare providers have been advised to make an earlier diagnosis of Alzheimer\u2019s, prior to individuals developing Alzheimer\u2019s disease dementia. Regrettably, the identification of early-stage Alzheimer\u2019s disease in clinical settings can be arduous due to the tendency of patients and healthcare providers to disregard symptoms as typical signs of aging. Therefore, accurate and prompt diagnosis of Alzheimer\u2019s disease is essential in order to facilitate the development of disease-modifying and secondary preventive therapies prior to the onset of symptoms. There has been a notable shift in the goal of the diagnosis process, transitioning from merely confirming the presence of symptomatic AD to recognizing the illness in its early, asymptomatic phases. Understanding the evolution of disease-modifying therapies and putting effective diagnostic and therapeutic management into practice requires an understanding of this concept. The outcomes of this study will enhance in-depth knowledge of the current status of Alzheimer\u2019s disease\u2019s diagnosis and treatment, justifying the necessity for the quest for potential novel biomarkers that can contribute to determining the stage of the disease, particularly in its earliest stages. Interestingly, latest clinical trial status on pharmacological agents, the nonpharmacological treatments such as behavior modification, exercise, and cognitive training as well as alternative approach on phytochemicals as neuroprotective agents have been covered in detailed.<\/jats:p>","DOI":"10.3389\/fnagi.2024.1429211","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T04:33:23Z","timestamp":1723178003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":60,"title":["Alzheimer\u2019s disease: a review on the current trends of the effective diagnosis and therapeutics"],"prefix":"10.3389","volume":"16","author":[{"given":"Aimi Syamima","family":"Abdul Manap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Almadodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheishinii Grace","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenil Sureshbhai","family":"Kavani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Elle","family":"Lyenouq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"B1","year":"2023","journal-title":"Alzheimer\u2019s disease and dementia."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1177392819866412","article-title":"Bacopa monnieri, a Neuroprotective Lead in Alzheimer disease: A review on its properties, mechanisms of action, and preclinical and clinical studies.","volume":"13","author":"Abdul Manap","year":"","journal-title":"Drug Target Insights"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00206","article-title":"Synergistic effects of curcumin and piperine as potent acetylcholine and amyloidogenic inhibitors with significant neuroprotective activity in SH-SY5Y cells via computational molecular modeling and in vitro assay.","volume":"11","author":"Abdul Manap","year":"","journal-title":"Front. Aging Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14283\/jpad.2016.115","article-title":"Clinical benefits of tramiprosate in Alzheimer\u2019s disease are associated with higher number of APOE4 alleles: The \u201cAPOE4 gene-dose effect.\u201d","volume":"3","author":"Abushakra","year":"2016","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0011-393X(03)00059-6","article-title":"Potent acetylcholinesterase inhibitors: Potential drugs for Alzheimer\u2019s disease.","volume":"20","author":"Ak\u0131nc\u0131o\u011flu","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","article-title":"Use of plasma biomarkers for AT (N) classification of neurodegenerative dementias.","volume":"92","author":"Alcolea","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00338","article-title":"Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability.","volume":"12","author":"Alonso","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1635","DOI":"10.1212\/WNL.0000000000008361","article-title":"Applying the ATN scheme in a memory clinic population: The ABIDE project.","volume":"93","author":"Altomare","year":"2019","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti\u2013\u03b2-amyloid drugs: A systematic review and meta-analysis.","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"B10","year":"2023","journal-title":"FAQ - Alzheimer\u2019s and dementia."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2.","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"key":"B12","first-page":"506","article-title":"\u00cdntomas neuropsiqui\u00e1tricos en el s\u00edndrome demencial.","volume":"38","author":"Artaso-Irigoyen","year":"2004","journal-title":"Rev. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40120-019-00168-1","article-title":"Salivary biomarkers for Alzheimer\u2019s disease and related disorders.","volume":"8","author":"Ashton","year":"2019","journal-title":"Neurol. Ther."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01417","article-title":"Natural products-based drugs: Potential therapeutics against Alzheimer\u2019s disease and other neurological disorders.","volume":"10","author":"Ayaz","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20199356","article-title":"Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer\u2019s disease.","volume":"16","author":"Bader","year":"2020","journal-title":"Mol. Syst. Biol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8100421","article-title":"Body fluid biomarkers for Alzheimer\u2019s disease\u2013an up-to-date overview.","volume":"8","author":"B\u0103la\u015fa","year":"2020","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3233\/JAD-220587","article-title":"Alzheimer\u2019s disease diagnosis based on the amyloid, tau, and neurodegeneration scheme (ATN) in a real-life multicenter cohort of general neurological centers.","volume":"90","author":"Baldeiras","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease.","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease.","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jnen\/nlac030","article-title":"history of senile plaques: From Alzheimer to amyloid imaging.","volume":"81","author":"Beach","year":"2022","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1177\/10497323231173854","article-title":"The experiences, needs, and solutions of caregivers of patients with behavioral and psychological symptoms of dementia living in residential and long-term care centers.","volume":"33","author":"B\u00e9langer-Dibblee","year":"2023","journal-title":"Qual. Health Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies.","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"B23","year":"2023","journal-title":"Dementia - activities and exercise."},{"key":"B24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/07334648221128283","article-title":"\u201cThe sun came up because you got here\u2026\u201d: A qualitative exploration of person-centered care strategies used by adult day care centers to manage behavioral and psychological symptoms of dementia.","volume":"42","author":"Boafo","year":"2023","journal-title":"J. Appl. Gerontol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00401-022-02418-3","article-title":"Donanemab detects a minor fraction of amyloid-\u03b2 plaques in post-mortem brain tissue of patients with Alzheimer\u2019s disease and Down syndrome.","volume":"143","author":"Bouter","year":"2022","journal-title":"Acta Neuropathol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: Causes and treatment.","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"B27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.phrs.2010.12.002","article-title":"The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer\u2019s disease and related tauopathies.","volume":"63","author":"Brunden","year":"2011","journal-title":"Pharmacol. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.","volume":"30","author":"Brunden","year":"2010","journal-title":"J. Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","article-title":"Alzheimer\u2019s disease neuroimaging initiative. Alzheimer\u2019s disease profiled by fluid and imaging markers: Tau PET best predicts cognitive decline.","volume":"26","author":"Bucci","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"B30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jalz.2017.07.241","article-title":"[O2\u201317\u201301]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER\u2019s DISEASE.","volume":"13","author":"Budur","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B31","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jm3017317","article-title":"Progress and developments in tau aggregation inhibitors for Alzheimer disease.","volume":"56","author":"Bulic","year":"2013","journal-title":"J. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3275\/8585","article-title":"The potential protective effect of tramiprosate (homotaurine) against Alzheimer\u2019s disease: A review.","volume":"24","author":"Caltagirone","year":"2012","journal-title":"Aging Clin. Exp. Res."},{"key":"B33","author":"Camporesi","year":"2021","journal-title":"Candidate biomarkers for synaptic pathology: Neurogranin, neuroligins and neurexins in neurodegenerative disorders"},{"key":"B34","first-page":"6","article-title":"FDA approves new treatment for Alzheimer\u2019s disease.","volume":"33","author":"Canady","year":"2023","journal-title":"Ment. Health Wkly."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/nu14040819","article-title":"Phenolic acids and prevention of cognitive decline: Polyphenols with a neuroprotective role in cognitive disorders and Alzheimer\u2019s disease.","volume":"14","author":"Caruso","year":"2022","journal-title":"Nutrients"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s40120-023-00526-0","article-title":"Potential ocular biomarkers for early detection of Alzheimer\u2019s disease and their roles in artificial intelligence studies.","volume":"12","author":"Chaitanuwong","year":"2023","journal-title":"Neurol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/joim.13329","article-title":"Induction of specific brain oscillations may restore neural circuits and be used for the treatment of Alzheimer\u2019s disease.","volume":"290","author":"Chan","year":"2021","journal-title":"J. Intern. Med."},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-023-00635-2","article-title":"The gut microbiome regulates astrocyte reaction to A\u03b2 amyloidosis through microglial dependent and independent mechanisms.","volume":"18","author":"Chandra","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"B39","article-title":"Disease progression modelling from preclinical Alzheimer\u2019s disease (AD) to AD dementia.","volume":"11","author":"Cho","year":"2021","journal-title":"Sci. Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/13803395.2023.2167942","article-title":"Predicting conversion of patients with Mild Cognitive Impairment to Alzheimer\u2019s disease using bedside cognitive assessments.","volume":"44","author":"Clarke","year":"2022","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12376","article-title":"State, trait, and accumulated features of the Alzheimer\u2019s disease assessment scale cognitive subscale (ADAS-Cog) in mild Alzheimer\u2019s disease.","volume":"9","author":"Cogo-Moreira","year":"2023","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030284","article-title":"A novel NMDA receptor antagonist protects against cognitive decline presented by senescent mice.","volume":"12","author":"Companys-Alemany","year":"2020","journal-title":"Pharmaceutics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: A randomized clinical trial.","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol."},{"key":"B44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/10762800152709741","article-title":"The plant alkaloid galantamine: Approved as a drug; sold as a supplement.","volume":"7","author":"Cronin","year":"2001","journal-title":"Altern. Complement. Ther."},{"key":"B45","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022.","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"B46","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer\u2019s disease drug development pipeline: 2019.","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"Role of BACE1 in Alzheimer\u2019s synaptic function.","volume":"6","author":"Das","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"B48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/fampra\/15.5.431","article-title":"The early diagnosis of dementia: Triggers, early signs and luxating events.","volume":"15","author":"De Lepeleire","year":"1998","journal-title":"Fam. Pract."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713429","article-title":"Tear liquid for predictive diagnosis of Alzheimer\u2019s disease.","volume":"4","author":"Del Prete","year":"2021","journal-title":"Y Rep."},{"key":"B50","year":"2022","journal-title":"Brain exercises for dementia: How they help the mind."},{"key":"B51","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease.","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/bmj.39429.434907.80","article-title":"Caring for people with dementia.","volume":"336","author":"Downs","year":"2008","journal-title":"BMJ"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer\u2019s disease: A new lexicon.","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria.","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease.","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/molecules28010417","article-title":"Neuroprotective effect of quercetin through targeting key genes involved in aluminum chloride induced Alzheimer\u2019s disease in rats.","volume":"10","author":"Elreedy","year":"2023","journal-title":"Egypt J. Basic Appl. Sci."},{"key":"B57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-323-85555-6.00001-1","article-title":"The shift to a proteinopenia paradigm in neurodegeneration.","volume":"193","author":"Ezzat","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"B58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bj.2018.03.004","article-title":"Salivary biomarkers for the diagnosis and monitoring of neurological diseases.","volume":"41","author":"Farah","year":"2018","journal-title":"Biomed. J."},{"key":"B59","article-title":"Revisions and updates to the Everyday Cognition (ECog) scales: Neuropsychology\/Early detection of cognitive decline with neuropsychological tests.","volume":"16","author":"Farias","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000450","article-title":"The measurement of everyday cognition (ECog): Revisions and updates.","volume":"35","author":"Farias","year":"2021","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B61","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1172\/JCI0215451","article-title":"Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.","volume":"110","author":"Fellner","year":"2002","journal-title":"J. Clin. Invest."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-87","article-title":"Behavioural symptoms in patients with Alzheimer\u2019s disease and their association with cognitive impairment.","volume":"10","author":"Fern\u00e1ndez","year":"2010","journal-title":"BMC Neurol."},{"key":"B63","first-page":"47","article-title":"Review of the advances in treatment for Alzheimer disease: Strategies for combating \u03b2-amyloid protein.","volume":"33","author":"Folch","year":"2018","journal-title":"Neurol. Engl."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1115721","article-title":"Anticholinergic effect of resveratrol with vitamin E on scopolamine-induced Alzheimer\u2019s disease in rats: Mechanistic approach to prevent inflammation.","volume":"14","author":"Foudah","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B65","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers.","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032590","article-title":"Beta-amyloid peptide in tears: An early diagnostic marker of Alzheimer\u2019s disease correlated with choroidal thickness.","volume":"24","author":"Gharbiya","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18031263","article-title":"Relation among caregivers\u2019 burden, abuse and behavioural disorder in people with dementia.","volume":"18","author":"Gimeno","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B68","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1089\/rej.2015.1791","article-title":"The effects of cognitive training for elderly: Results from my mind project.","volume":"19","author":"Giuli","year":"2016","journal-title":"Rejuvenation Res."},{"key":"B69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13311-022-01201-2","article-title":"Disease-modifying therapies for Alzheimer\u2019s disease: More questions than answers.","volume":"19","author":"Golde","year":"2023","journal-title":"Neurotherapeutics"},{"key":"B70","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/1073191121991215","article-title":"Comprehensive evaluation of the functional activities questionnaire (FAQ) and its reliability and validity.","volume":"29","author":"Gonz\u00e1lez","year":"2022","journal-title":"Assessment"},{"key":"B71","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1476-5381.2011.01713.x","article-title":"Tau-targeted treatment strategies in Alzheimer\u2019s disease.","volume":"165","author":"G\u00f6tz","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102161","article-title":"Once upon a time, the amyloid cascade hypothesis.","volume":"2023","author":"Granzotto","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"B73","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial.","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"B74","doi-asserted-by":"crossref","first-page":"M331","DOI":"10.1093\/gerona\/58.4.M331","article-title":"Management of Alzheimer\u2019s disease.","volume":"58","author":"Grossberg","year":"2003","journal-title":"J. Gerontol. Ser. A"},{"key":"B75","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/01616412.2023.2203615","article-title":"Brain-targeted lycopene-loaded microemulsion modulates neuroinflammation, oxidative stress, apoptosis and synaptic plasticity in \u03b2-amyloid-induced Alzheimer\u2019s disease mice.","volume":"45","author":"Guo","year":"2023","journal-title":"Neurol. Res."},{"key":"B76","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106549","article-title":"Current druggable targets for therapeutic control of Alzheimer\u2019s disease.","volume":"109","author":"Gupta","year":"2021","journal-title":"Contemp Clin. Trials"},{"key":"B77","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease.","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"B78","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neurobiolaging.2008.03.027","article-title":"Evaluation of plasma A\u03b240 and A\u03b242 as predictors of conversion to Alzheimer\u2019s disease in patients with mild cognitive impairment.","volume":"31","author":"Hansson","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"B79","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/jnnp-2013-306285","article-title":"An algorithmic approach to structural imaging in dementia.","volume":"85","author":"Harper","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"B80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.31887\/DCNS.2019.21.3\/pharvey","article-title":"Domains of cognition and their assessment.","volume":"21","author":"Harvey","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3233\/JAD-150852","article-title":"Describing the sequence of cognitive decline in Alzheimer\u2019s disease patients: Results from an observational study.","volume":"52","author":"Henneges","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer\u2019s disease.","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B83","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/070674371405901202","article-title":"Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.","volume":"59","author":"Hogan","year":"2014","journal-title":"Can. J. Psychiatry Rev. Can. Psychiatr."},{"key":"B84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease.","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/psyg.12558","article-title":"Use of day services improved cognitive function in patients with Alzheimer\u2019s disease.","volume":"20","author":"Honjo","year":"2020","journal-title":"Psychogeriatrics"},{"key":"B86","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer\u2019s disease.","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2016.00013","article-title":"Diagnostic value of microRNA for Alzheimer\u2019s disease: A systematic review and meta-analysis.","volume":"8","author":"Hu","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-023-00976-6","article-title":"Clinical trials of new drugs for Alzheimer disease: A 2020\u20132023 update.","volume":"30","author":"Huang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"B89","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1567205014666170117101537","article-title":"Long-Term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer\u2019s disease.","volume":"14","author":"Hull","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"B90","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/gps.2204","article-title":"Primary care and dementia: 1. diagnosis, screening and disclosure.","volume":"24","author":"Iliffe","year":"2009","journal-title":"Int. J. Geriatr. Psychiatry J. Psychiatry Late Life Allied Sci."},{"key":"B91","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","article-title":"Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease.","volume":"28","author":"Imbimbo","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B92","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","article-title":"Determining clinically meaningful decline in preclinical Alzheimer disease.","volume":"93","author":"Insel","year":"2019","journal-title":"Neurology."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2020.00648","article-title":"Technologies for cognitive training and cognitive rehabilitation for people with mild cognitive impairment and dementia. A systematic review.","volume":"11","author":"Irazoki","year":"2020","journal-title":"Front. Psychol."},{"key":"B94","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jalz.2016.06.665","article-title":"O4-08-06: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A \u03b2\u2212AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER\u2019S DISEASE (AD).","volume":"12","author":"Irizarry","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160979","article-title":"The Mild Behavioral Impairment Checklist (MBI-C): A rating scale for neuropsychiatric symptoms in pre-dementia populations.","volume":"56","author":"Ismail","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B97","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"B98","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.2019.7437","article-title":"Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia.","volume":"321","author":"Jack","year":"2019","journal-title":"JAMA"},{"key":"B99","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia.","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease.","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci. Rep."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-019-1175-2","article-title":"Effects of physical activity and exercise on the cognitive function of patients with Alzheimer disease: A meta-analysis.","volume":"19","author":"Jia","year":"2019","journal-title":"BMC Geriatr."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00254","article-title":"Role of neurofilament light chain as a potential biomarker for Alzheimer\u2019s disease: A correlative meta-analysis.","volume":"11","author":"Jin","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"B103","first-page":"130","article-title":"The Wisconsin Registry for Alzheimer\u2019s Prevention: A review of findings and current directions.","volume":"10","author":"Johnson","year":"2018","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit."},{"key":"B104","year":"2023","journal-title":"Representing the elderly client or the client with diminished capacity."},{"key":"B105","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1586\/ern.11.155","article-title":"Distinguishing Alzheimer\u2019s disease from other major forms of dementia.","volume":"11","author":"Karantzoulis","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts.","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"B107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713429","article-title":"Tear biomarkers and Alzheimer\u2019s Disease.","volume":"24","author":"Ka\u0161telan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-016-0119-y","article-title":"Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: Emerging therapeutic modality for Alzheimer\u2019s disease.","volume":"11","author":"Kazim","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"B109","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1021\/cr300009x","article-title":"Bioinorganic chemistry of Alzheimer\u2019s disease.","volume":"112","author":"Kepp","year":"2012","journal-title":"Chem. Rev."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-021-02109-w","article-title":"Behavioural and psychological symptoms of dementia in patients with Alzheimer\u2019s disease and family caregiver burden: A path analysis.","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Geriatr."},{"key":"B111","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","article-title":"Neuropathology of cognitively normal elderly.","volume":"62","author":"Knopman","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00803-w","article-title":"Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer\u2019s disease already receiving donepezil: A phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.","volume":"13","author":"Koh","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"B113","article-title":"The effectiveness of occupational therapy for persons with moderate and severe dementia.","volume":"9","author":"Korczak","year":"2013","journal-title":"GMS Health Technol. Assess."},{"key":"B114","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228651","article-title":"Therapeutic strategies to reduce the toxicity of misfolded protein oligomers.","volume":"21","author":"Kreiser","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JAD-170991","article-title":"The Alzheimer\u2019s disease assessment scale\u2013cognitive subscale (ADAS-Cog): Modifications and responsiveness in pre-dementia populations. A narrative review.","volume":"63","author":"Kueper","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B116","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B117","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/07315724.2022.2062488","article-title":"Neuroprotective effects of hesperidin and naringin in SK-N-AS cell as an in vitro model for Alzheimer\u2019s disease.","volume":"42","author":"Ku\u015fi","year":"2023","journal-title":"J. Am. Nutr. Assoc."},{"key":"B118","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2019.1665453","article-title":"Rationale for the development of an Alzheimer\u2019s disease vaccine.","volume":"16","author":"Kwan","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"B119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2 40 vaccine (ABvac40) in patients with Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled, phase i trial.","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"B120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41573-022-00390-x","article-title":"Function and therapeutic value of astrocytes in neurological diseases.","volume":"21","author":"Lee","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0299-y","article-title":"Diagnosis of Alzheimer\u2019s disease utilizing amyloid and tau as fluid biomarkers.","volume":"51","author":"Lee","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00415-022-11423-1","article-title":"Brain structural abnormalities and cognitive changes in a patient with 17q21. 31 microduplication and early onset dementia: A case report.","volume":"270","author":"Leocadi","year":"2023","journal-title":"J. Neurol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1385\/JMN:23:1-2:115","article-title":"Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer\u2019s disease: Original data and review of the literature.","volume":"23","author":"Lewczuk","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010966","article-title":"Comparison of the value of Mini-Cog and MMSE screening in the rapid identification of Chinese outpatients with mild cognitive impairment.","volume":"97","author":"Li","year":"2018","journal-title":"Medicine"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.937486","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132019.","volume":"14","author":"Li","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1172\/JCI21746","article-title":"Amyloid at the cutting edge: Activation of \u03b1-secretase prevents amyloidogenesis in an Alzheimer disease mouse model.","volume":"113","author":"Lichtenthaler","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B127","article-title":"History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease.","volume":"4","author":"Liu","year":"2019","journal-title":"Signal. Transduct. Target. Ther."},{"key":"B128","first-page":"227","author":"Livingston","year":"2019","journal-title":"Current and future treatments in Alzheimer\u2019s disease."},{"key":"B129","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.trci.2019.02.005","article-title":"The Alzheimer\u2019s Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer\u2019s disease.","volume":"5","author":"Lopez","year":"2019","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"B130","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.archger.2007.07.010","article-title":"Trazodone for Alzheimer\u2019s disease: A naturalistic follow-up study.","volume":"47","author":"L\u00f3pez-Pousa","year":"2008","journal-title":"Arch. Gerontol. Geriatr."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3758\/s13421-022-01373-4","article-title":"Effects of acute exercise on memory: Considerations of exercise intensity, post-exercise recovery period and aerobic endurance.","volume":"51","author":"Loprinzi","year":"2023","journal-title":"Mem. Cognit."},{"key":"B132","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-160835","article-title":"MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer\u2019s disease.","volume":"55","author":"Lusardi","year":"2017","journal-title":"J Alzheimers Dis."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01168","article-title":"Pharmacotherapy of behavioral and psychological symptoms of dementia: State of the art and future progress.","volume":"11","author":"Magierski","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.720167","article-title":"Ophthalmic biomarkers for Alzheimer\u2019s disease: A review.","volume":"13","author":"Majeed","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2018.00509","article-title":"Effects of physical exercise on cognitive functioning and wellbeing: Biological and psychological benefits.","volume":"9","author":"Mandolesi","year":"2018","journal-title":"Front. Psychol."},{"key":"B136","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-031-27968-3_22","author":"Manni","year":"2023","journal-title":"Neurodegenerative disorders\/dementia: Noninvasive mechanical ventilation and neuropsychiatric disorders: Essential practical approaches."},{"key":"B137","article-title":"Saffron reduces some inflammation and oxidative stress markers in donepezil-treated mild-to-moderate Alzheimer\u2019s disease patients: A randomized double-blind placebo-control trial.","volume":"34","author":"Marzabadi","year":"2022","journal-title":"J. Herb. Med."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123289","article-title":"Memantine monotherapy for Alzheimer\u2019s disease: A systematic review and meta-analysis.","volume":"10","author":"Matsunaga","year":"2015","journal-title":"PLoS One"},{"key":"B139","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease.","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"B140","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"B141","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3233\/JAD-160488","article-title":"Inflammation, antiinflammatory agents, and Alzheimer\u2019s disease: The last 22 years.","volume":"54","author":"McGeer","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B142","year":"2023","journal-title":"Activities for dementia: Ideas for caregivers to try."},{"key":"B143","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041160","article-title":"An overview on the clinical development of tau-based therapeutics.","volume":"19","author":"Medina","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B144","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.nicl.2016.12.011","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative. Rey\u2019s auditory verbal learning test scores can be predicted from whole brain MRI in Alzheimer\u2019s disease.","volume":"13","author":"Moradi","year":"2017","journal-title":"Neuroimage Clin."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170547","article-title":"Aerobic exercise for Alzheimer\u2019s disease: A randomized controlled pilot trial.","volume":"12","author":"Morris","year":"2017","journal-title":"PLoS One"},{"key":"B146","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer\u2019s disease.","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"B147","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/idoj.IDOJ_475_18","article-title":"Clinical trial designs.","volume":"10","author":"Nair","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"B148","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40120-022-00428-7","article-title":"The early diagnosis of Alzheimer\u2019s disease: A patient-centred conversation with the care team.","volume":"12","author":"Nasreddine","year":"2023","journal-title":"Neurol. Ther."},{"key":"B149","year":"2023","journal-title":"Alzheimer\u2019s disease fact sheet."},{"key":"B150","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/msj.20279","article-title":"Alzheimer\u2019s disease: Diagnosis and treatment across the spectrum of disease severity.","volume":"78","author":"Neugroschl","year":"2011","journal-title":"Mt. Sinai J. Med. N. Y."},{"key":"B151","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/JAD-170327","article-title":"The cerebrospinal fluid A\u03b2 1\u201342\/A\u03b2 1\u201340 ratio improves concordance with amyloid-PET for diagnosing Alzheimer\u2019s disease in a clinical setting.","volume":"60","author":"Niemantsverdriet","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B152","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020195","article-title":"Epigenetics of Alzheimer\u2019s disease.","volume":"11","author":"Nikolac Perkovic","year":"2021","journal-title":"Biomolecules"},{"key":"B153","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","article-title":"The development and validation of tau PET tracers: Current status and future directions.","volume":"6","author":"Okamura","year":"2018","journal-title":"Clin. Transl. Imaging"},{"key":"B154","doi-asserted-by":"crossref","first-page":"213","DOI":"10.11622\/smedj.2021057","article-title":"Family engagement as part of managing patients with mental illness in primary care.","volume":"62","author":"Ong","year":"2021","journal-title":"Singapore Med. J."},{"key":"B155","article-title":"Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.","volume":"2014","author":"Orgeta","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B156","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3245935","article-title":"Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease.","volume":"2016","author":"Panza","year":"2016","journal-title":"BioMed Res. Int."},{"key":"B158","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/13854046.2014.911351","article-title":"Development of a psychometrically equivalent short form of the face\u2013name associative memory exam for use along the early Alzheimer\u2019s disease trajectory.","volume":"28","author":"Papp","year":"2014","journal-title":"Clin. Neuropsychol."},{"key":"B159","doi-asserted-by":"crossref","DOI":"10.3390\/app13031656","article-title":"Marital status of never married with rey auditory verbal learning test cognition performance is associated with mild cognitive impairment.","volume":"13","author":"Parra Bautista","year":"2023","journal-title":"Appl. Sci."},{"key":"B160","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41582-023-00822-1","article-title":"Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration.","volume":"19","author":"Patani","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"B161","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11020371","article-title":"The role of salivary biomarkers in the early diagnosis of Alzheimer\u2019s disease and Parkinson\u2019s disease.","volume":"11","author":"Pawlik","year":"2021","journal-title":"Diagnostics"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2174\/1567205017666191213162233","article-title":"Brain arrhythmias induced by amyloid beta and inflammation: Involvement in Alzheimer\u2019s disease and other inflammation-related pathologies.","volume":"16","author":"Pe\u00f1a-Ortega","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3233\/JAD-160275","article-title":"Pharmacological agents targeting \u03b3-secretase increase risk of cancer and cognitive decline in Alzheimer\u2019s disease patients: A systematic review and meta-analysis.","volume":"53","author":"Penninkilampi","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B164","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1093\/brain\/awt171","article-title":"Dissecting phenotypic traits linked to human resilience to Alzheimer\u2019s pathology.","volume":"136","author":"Perez-Nievas","year":"2013","journal-title":"Brain"},{"key":"B165","year":"2023","journal-title":"Roles of the multidisciplinary team in discharge planning from hospital."},{"key":"B166","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3233\/JAD-160122","article-title":"Amyloid-Related Imaging Abnormalities (ARIA) in immunotherapy trials for Alzheimer\u2019s disease: Need for prognostic biomarkers?","volume":"52","author":"Piazza","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: A secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial.","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"B168","first-page":"371","article-title":"Diagnosis of early Alzheimer\u2019s disease: Clinical practice in 2021.","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B169","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26175327","article-title":"Therapeutic potential of natural products in treating neurodegenerative disorders and their future prospects and challenges.","volume":"26","author":"Rahman","year":"2021","journal-title":"Molecules"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.648310","article-title":"The role of brief global cognitive tests and neuropsychological expertise in the detection and differential diagnosis of dementia.","volume":"13","author":"Riello","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00651-2","article-title":"Misfolded protein oligomers: Mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases.","volume":"19","author":"Rinauro","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"B172","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease.","volume":"20","author":"Rissman","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B173","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting.","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurol."},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054353","article-title":"Molecular mechanisms of the protective effects of olive leaf polyphenols against Alzheimer\u2019s disease.","volume":"24","author":"Romero-M\u00e1rquez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B175","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/384875","article-title":"Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: A review.","volume":"2012","author":"Ruthirakuhan","year":"2012","journal-title":"J. Aging Res."},{"key":"B176","first-page":"69","author":"Schmidt","year":"2022","journal-title":"Pharmacology of NMDA (N-methyl-D-aspartate) receptor antagonists in Alzheimer\u2019s disease: Pharmacological treatment of Alzheimer\u2019s disease: Scientific and clinical aspects."},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32951-4","article-title":"Structure-based discovery of small molecules that disaggregate Alzheimer\u2019s disease tissue derived tau fibrils in vitro.","volume":"13","author":"Seidler","year":"2022","journal-title":"Nat. Commun."},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1126\/science.add1236","article-title":"ApoE isoform\u2013and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy.","volume":"379","author":"Seo","year":"2023","journal-title":"Science"},{"key":"B179","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3\u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo.","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"B180","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease.","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B181","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174455","article-title":"Memantine and its benefits for cancer, cardiovascular and neurological disorders.","volume":"910","author":"Shafiei-Irannejad","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B182","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: The TRAILBLAZER-ALZ randomized clinical trial.","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"B183","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/978-981-32-9358-8_29","article-title":"Cerebrospinal fluid and plasma tau as a biomarker for brain tauopathy.","volume":"1184","author":"Shoji","year":"2019","journal-title":"Tau Biol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/JAD-221222","article-title":"Molecular docking and network pharmacology interaction analysis of gingko biloba (egb761) extract with dual target inhibitory mechanism in Alzheimer\u2019s disease.","volume":"93","author":"Singh","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"B185","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1212\/WNL.0000000000007248","article-title":"ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.","volume":"92","author":"Soldan","year":"2019","journal-title":"Neurology"},{"key":"B186","doi-asserted-by":"crossref","DOI":"10.15698\/cst2018.11.162","article-title":"Making the final cut: Pathogenic amyloid-\u03b2 peptide generation by \u03b3-secretase.","volume":"2","author":"Steiner","year":"2018","journal-title":"Cell Stress"},{"key":"B187","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/JAD-220808","article-title":"High soluble amyloid-\u03b2 42 predicts normal cognition in amyloid-positive individuals with Alzheimer\u2019s disease-causing mutations.","volume":"90","author":"Sturchio","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"B188","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100988","article-title":"High cerebrospinal amyloid-\u03b2 42 is associated with normal cognition in individuals with brain amyloidosis.","volume":"38","author":"Sturchio","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B189","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected.","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1129510","article-title":"Vibrotactile stimulation at gamma frequency mitigates pathology related to neurodegeneration and improves motor function.","volume":"15","author":"Suk","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"B191","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/CIA.S394821","article-title":"Early diagnosis of Alzheimer\u2019s disease: Moving toward a blood-based biomarkers era.","volume":"18","author":"Tao","year":"2023","journal-title":"Clin. Interv. Aging"},{"key":"B192","first-page":"156","article-title":"Treating psychotic symptoms in elderly patients.","volume":"3","author":"Targum","year":"2001","journal-title":"Prim. Care Comp. J. Clin. Psychiatry"},{"key":"B193","first-page":"1152","article-title":"Behavioral or neuropsychiatric symptoms of Alzheimer\u2019s disease: From psychopathology to pharmacological management.","volume":"81","author":"Teixeira","year":"2024","journal-title":"Arq. Neuropsiquiatr."},{"key":"B194","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1385\/NMM:2:2:151","article-title":"Axonal transport, tau protein, and neurodegeneration in Alzheimer\u2019s disease.","volume":"2","author":"Terwel","year":"2002","journal-title":"Neuromolecular Med."},{"key":"B195","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3233\/JAD-170784","article-title":"Plasma amyloid-\u03b2 (A\u03b2 42) correlates with cerebrospinal fluid A\u03b2 42 in Alzheimer\u2019s disease.","volume":"62","author":"Teunissen","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B196","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration.","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med."},{"key":"B197","first-page":"41","article-title":"Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics.","volume":"55","author":"Tiwari","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"B198","first-page":"274","article-title":"Financial management skills in aging, MCI and dementia: Cross sectional relationship to 18F-florbetapir PET cortical \u03b2-amyloid deposition.","volume":"6","author":"Tolbert","year":"2019","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113098","article-title":"Novel therapeutic strategies in Alzheimer\u2019s disease: Pitfalls and challenges of anti-amyloid therapies and beyond.","volume":"13","author":"Tondo","year":"2024","journal-title":"J. Clin. Med."},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2021.782399","article-title":"Gamma oscillations in Alzheimer\u2019s disease and their potential therapeutic role.","volume":"15","author":"Traikapi","year":"2021","journal-title":"Front. Syst. Neurosci."},{"key":"B201","article-title":"Cognitive training in patients with Alzheimer\u2019s disease: Findings of a 12-month randomized controlled trial.","volume":"2","author":"Trebbastoni","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"B202","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: A randomized clinical trial.","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol."},{"key":"B203","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.","volume":"43","author":"Tucker","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1021792","article-title":"Sum of boxes of the clinical dementia rating scale highly predicts conversion or reversion in predementia stages.","volume":"14","author":"Tzeng","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"B205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B206","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1474-4422(19)30283-2","article-title":"Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): A modelling study.","volume":"18","author":"van Maurik","year":"2019","journal-title":"Lancet Neurol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimer\u2019s disease: A 3-month, randomized, placebo-controlled, double-blind study.","volume":"8","author":"Vellas","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"B208","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype.","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030061","article-title":"Molecular and imaging biomarkers in Alzheimer\u2019s disease: A focus on recent insights.","volume":"10","author":"Villa","year":"2020","journal-title":"J. Pers. Med."},{"key":"B210","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.arr.2016.01.004","article-title":"Neuroimaging biomarkers in Alzheimer\u2019s disease and other dementias.","volume":"30","author":"Villemagne","year":"2016","journal-title":"Ageing Res. Rev."},{"key":"B211","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/hbm.24401","article-title":"Data-driven approaches for tau-PET imaging biomarkers in Alzheimer\u2019s disease.","volume":"40","author":"Vogel","year":"2019","journal-title":"Hum. Brain Mapp."},{"key":"B212","author":"Wall","year":"2024","journal-title":"Lilly\u2019s Kisunla\u2122 (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer\u2019s disease."},{"key":"B213","doi-asserted-by":"crossref","first-page":"22364","DOI":"10.1074\/jbc.272.35.22364","article-title":"Amyloid fibrillogenesis: Detection of a protofibrillar intermediate","volume":"272","author":"Walsh","year":"1997","journal-title":"J. Biol. Chem"},{"key":"B214","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1021\/acschemneuro.8b00391","article-title":"Reconsideration of anticholinesterase therapeutic strategies against Alzheimer\u2019s disease.","volume":"10","author":"Wang","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"B215","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s12144-023-04281-1","article-title":"Cognitive and behavioral abnormalities in individuals with Alzheimer\u2019s disease, mild cognitive impairment, and subjective memory complaints.","volume":"43","author":"Warren","year":"2023","journal-title":"Curr. Psychol."},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1591-0","article-title":"Cerebro-spinal fluid biomarker levels: Phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer\u2019s disease.","volume":"20","author":"Wattmo","year":"2020","journal-title":"BMC Neurol."},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12312","article-title":"Integrated Alzheimer\u2019s disease rating scale: Clinically meaningful change estimates.","volume":"8","author":"Wessels","year":"2022","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"B218","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis (hydromethanesulphonate)(LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: Cohort analysis as modified primary outcome in a phase III clinical trial.","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B219","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease.","volume":"44","author":"Wischik","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"B220","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/cbdd.14041","article-title":"Ginsenoside Rg1 improves Alzheimer\u2019s disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt\/GSK-3\u03b2\/\u03b2\u2212catenin signaling pathway.","volume":"99","author":"Yang","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23676-w","article-title":"Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: A three-year longitudinal study.","volume":"8","author":"Ye","year":"2018","journal-title":"Sci. Rep."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00612-7","article-title":"Imaging biomarkers in neurodegeneration: Current and future practices.","volume":"12","author":"Young","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"B223","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.jalz.2019.05.006","article-title":"Frequency and longitudinal clinical outcomes of Alzheimer\u2019s AT (N) biomarker profiles: A longitudinal study.","volume":"15","author":"Yu","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B224","doi-asserted-by":"crossref","first-page":"273","DOI":"10.47102\/annals-acadmedsg.V45N7p273","article-title":"Psychometric properties of Alzheimer\u2019s disease assessment scale-cognitive subscale for mild cognitive impairment and mild Alzheimer\u2019s disease patients in an Asian context.","volume":"45","author":"Zainal","year":"2016","journal-title":"Ann. Acad. Med. Singap."},{"key":"B225","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/ajhp\/60.5.446","article-title":"Galantamine hydrobromide: An agent for Alzheimer\u2019s disease.","volume":"60","author":"Zarotsky","year":"2003","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B226","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.1523\/JNEUROSCI.2357-10.2010","article-title":"\u03b2 oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.","volume":"30","author":"Zempel","year":"2010","journal-title":"J. Neurosci."},{"key":"B227","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B228","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s00259-021-05230-5","article-title":"PET imaging of neural activity, \u03b2-amyloid, and tau in normal brain aging.","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B229","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2217\/bmm-2018-0341","article-title":"Blood circulating miRNAs as biomarkers of Alzheimer\u2019s disease: A systematic review and meta-analysis.","volume":"13","author":"Zhang","year":"2019","journal-title":"Biomark. Med."},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: Challenges, successes and future.","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"B231","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/alz.12328","article-title":"Alzheimer\u2019s disease facts and figures.","volume":"16","author":"Zhao","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.585432","article-title":"microRNA-based biomarkers in Alzheimer\u2019s disease (AD).","volume":"14","author":"Zhao","year":"2020","journal-title":"Front. Neurosci."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1429211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T04:34:40Z","timestamp":1723178080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1429211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":232,"alternative-id":["10.3389\/fnagi.2024.1429211"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2024.1429211","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"article-number":"1429211"}}